» Articles » PMID: 12057925

Synergistic Up-regulation of Vascular Endothelial Growth Factor Expression in Murine Macrophages by Adenosine A(2A) Receptor Agonists and Endotoxin

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2002 Jun 12
PMID 12057925
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Under normoxic conditions, macrophages from C57BL mice produce low levels of vascular endothelial growth factor (VEGF). Hypoxia stimulates VEGF expression by approximately 500%; interferon-gamma (IFN-gamma) with endotoxin [lipopolysaccharide (LPS)] also stimulates VEGF expression by approximately 50 to 150% in an inducible nitric oxide synthase (iNOS)-dependent manner. Treatment of normoxic macrophages with 5'-N-ethyl-carboxamido-adenosine (NECA), a nonselective adenosine A(2) receptor agonist, or with 2-[p-(2-carboxyethyl)-phenylethyl amino]-5'-N-ethyl-carboxamido-adenosine (CGS21680), a specific adenosine A(2A) receptor agonist, modestly increases VEGF expression, whereas 2-chloro-N(6)-cyclopentyl adenosine (CCPA), an adenosine A(1) agonist, does not. Treatment with LPS (0 to 1000 ng/ml), or with IFN-gamma (0 to 300 U/ml), does not affect VEGF expression. In the presence of LPS (EC(50) < 10 ng/ml), but not of IFN-gamma, both NECA and CGS21680 synergistically up-regulate VEGF expression by as much as 10-fold. This VEGF is biologically active in vivo in the rat corneal bioassay of angiogenesis. Inhibitors of iNOS do not affect this synergistic induction of VEGF, and macrophages from iNOS-/- mice produce similar levels of VEGF as wild-type mice, indicating that NO does not play a role in this induction. Under hypoxic conditions, VEGF expression is slightly increased by adenosine receptor agonists but adenosine A(2) or A(1) receptor antagonists 3,7-dimethyl-1-propargyl xanthine (DMPX), ZM241385, and 8-cyclopentyl-1,3-dipropylxanthine (DCPCX) do not modulate VEGF expression. VEGF expression is also not reduced in hypoxic macrophages from A(3)-/- and A(2A)-/- mice. Thus, VEGF expression by hypoxic macrophages does not seem to depend on endogenously released or exogenous adenosine. VEGF expression is strongly up-regulated by LPS/NECA in macrophages from A(3)-/- but not A(2A)-/- mice, confirming the role of adenosine A(2A) receptors in this pathway. LPS with NECA strongly up-regulates VEGF expression by macrophages from C(3)H/HeN mice (with intact Tlr4 receptors), but not by macrophages from C(3)H/HeJ mice (with mutated, functionally inactive Tlr4 receptors), implicating signaling through the Tlr4 pathway in this synergistic up-regulation. Finally, Western blot analysis of adenosine A(2A) receptor expression indicated that the synergistic interaction of LPS with A(2A) receptor agonists does not involve up-regulation of A(2A) receptors by LPS. These results indicate that in murine macrophages there is a novel pathway regulating VEGF production, that involves the synergistic interaction of adenosine A(2A) receptor agonists through A(2A) receptors with LPS through the Tlr4 pathway, resulting in the strong up-regulation of VEGF expression by macrophages in a hypoxia- and NO-independent manner.

Citing Articles

Adenosine signaling in tumor-associated macrophages and targeting adenosine signaling for cancer therapy.

Yang L, Zhang Y, Yang L Cancer Biol Med. 2024; 21(11).

PMID: 39629670 PMC: 11667779. DOI: 10.20892/j.issn.2095-3941.2024.0228.


The Essential Role of Angiogenesis in Adenosine 2A Receptor Deficiency-mediated Impairment of Wound Healing Involving c-Ski via the ERK/CREB Pathways.

Peng Y, Xiong R, Wang B, Chen X, Ning Y, Zhao Y Int J Biol Sci. 2024; 20(11):4532-4550.

PMID: 39247808 PMC: 11380447. DOI: 10.7150/ijbs.98856.


Histone H3 posttranslational modified enzymes defined neutrophil plasticity and their vulnerability to IL-10 in the course of the inflammation.

Piatek P, Namiecinska M, Lewkowicz N, Kulinska-Michalska M, Jablonowski Z, Matysiak M J Inflamm (Lond). 2024; 21(1):16.

PMID: 38745328 PMC: 11095086. DOI: 10.1186/s12950-024-00389-8.


Targeting adenosine A receptors for early intervention of retinopathy of prematurity.

Chen X, Sun X, Ge Y, Zhou X, Chen J Purinergic Signal. 2024; .

PMID: 38329708 DOI: 10.1007/s11302-024-09986-x.


Adenosine, bridging chronic inflammation and tumor growth.

Chen L, Alabdullah M, Mahnke K Front Immunol. 2023; 14:1258637.

PMID: 38022572 PMC: 10643868. DOI: 10.3389/fimmu.2023.1258637.


References
1.
Priebe T, Platsoucas C, Nelson J . Adenosine receptors and modulation of natural killer cell activity by purine nucleosides. Cancer Res. 1990; 50(14):4328-31. View

2.
Chen J, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D . A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci. 1999; 19(21):9192-200. PMC: 6782932. View

3.
Ritchie P, Spangelo B, Krzymowski D, Rossiter T, Kurth E, Judd A . Adenosine increases interleukin 6 release and decreases tumour necrosis factor release from rat adrenal zona glomerulosa cells, ovarian cells, anterior pituitary cells, and peritoneal macrophages. Cytokine. 1997; 9(3):187-98. DOI: 10.1006/cyto.1996.0153. View

4.
Semenza G . HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol (1985). 2000; 88(4):1474-80. DOI: 10.1152/jappl.2000.88.4.1474. View

5.
Beutler B, Poltorak A . Positional cloning of Lps, and the general role of toll-like receptors in the innate immune response. Eur Cytokine Netw. 2000; 11(2):143-52. View